Keyword: Johns Hopkins

Suppressing the YAP protein, known for its role in modulating cell death, may help free up the immune system to fight cancer.

A startup from Johns Hopkins launched with $36 million to bring a potentially disease-modifying drug into phase 1 for Parkinson’s disease.

The past week saw the discovery of a genetic mutation that disrupts nerve signaling in ALS and the development of a noninvasive bladder cancer test.

Dracen will advance drugs that stifle a tumor's energy source and boost the immune response to cancer.

California researchers have gained insight into how a 30-year-old asthma drug called amlexanox helps burn calories—and it all ties into inflammation.

Researchers at Johns Hopkins have developed a noninvasive blood test that can detect signs of eight different types of cancer before symptoms begin.

The past week ushered in new discoveries of combination treatments for lung cancer and lymphoma, and nonopioid pain relief inspired by venomous sea creatures.

Johns Hopkins researchers are altering the gut microbiome of mosquitoes to reduce the spread of malaria.

Harvard University researchers have identified an enzyme that protects cells from harmful fats, which could inform new obesity treatments.

Johns Hopkins spinout Sonavex reeled in $3 million, including $2.2 million from the first close of its Series A round for its ultrasound blood-clot detector.